A B S T R A C T The influence of catecholamines on growth hormone secretion has been difficult to establish previously, possibly because of the suppressive effect of the induced hyperglycemia on growth hormone concentrations. In this study, an adrenergic receptor control mechanism for human growth hormone (HGH) secretion was uncovered by studying the effects of alpha and beta receptor blockade on insulin-induced growth hormone elevations in volunteer subjects.
A B S T R A C T The influence of catecholamines on growth hormone secretion has been difficult to establish previously, possibly because of the suppressive effect of the induced hyperglycemia on growth hormone concentrations. In this study, an adrenergic receptor control mechanism for human growth hormone (HGH) secretion was uncovered by studying the effects of alpha and beta receptor blockade on insulin-induced growth hormone elevations in volunteer subjects.
Alpha adrenergic blockade with phentolamine during insulin hypoglycemia, 0.1 U/kg, inhibited growth hormon elevations to 30-50% of values in the same subjects during insulin hypoglycemia without adrenergic blockade. More complete inhibition by phentolamine could not be demonstrated at a lower dose of insulin (0.05 U/kg). Beta adrenergic blockade with propranolol during insulin hypoglycemia significantly enhanced HGH concentrations in paired experiments. The inhibiting effect of alpha adrenergic receptor blockade on HGH concentrations could not be attributed to differences in blood glucose or free fatty acid values; however, more prolonged hypoglycemia and lower plasma free fatty acid values may have been a factor in the greater HGH concentrations observed during beta blockade. In the absence of insulin induced hypoglycemia, neither alpha nor beta adrenergic receptor blockade had a detectable
INTRODUCTION
Many of the stimuli for growth hormone secretion such as physical and surgical stress (1, 2) , psychic stress (2) , exercise (2), 2-deoxyglucose (1), hypoglycemia (1) , histamine (3) , vasopressin (4) , and pyrogen (5) result in increased catecholamine concentrations in blood and tissues (2, (6) (7) (8) (9) (10) . The control of pituitary growth hormone secretion by the hypothalamus is now widely accepted and recent evidence has shown that at least one of the above mentioned stimuli caused a discharge of growth hormone-releasing factor from the hypothalamus (11) . As the catecholamine content of the hypothalamus is higher than that of any other central nervous system structure (12) , the possibility that the effect of these stimuli on growth hormone secretion may be mediated by catecholamines must be considered.
The role of epinephrine in the control of growth hormone secretion has been controversial. Two groups of investigators (13, 14) have detected a stimulatory effect of epinephrine on growth hormone secretion while other investigators have been unable to demonstrate elevated growth hormone concentrations after epinephrine administration (2, 6, 15, 16) . Perhaps epinephrine-induced hyperglycemia masked a stimulatory effect of the hormone on growth hormone secretion in the negative studies since hyperglycemia suppresses plasma growth hormone concentrations (1) .
The present investigation was performed (a) to determine the effect of catecholamines on growth hormone secretion under conditions in which hyperglycemia could not mask a stimulatory effect, (b) to characterize any observed effect in terms of alpha and beta adrenergic receptors, and (c) to assess the role of endogenous catecholamines on the plasma growth hormone response to insulin hypoglycemia. Administration of alpha and beta adrenergic blocking agents during insulin hypoglycemia to determine their effect on plasma human growth hormone (HGH) elevations proved a suitable experimental design for these purposes.
METHODS
21 apparently healthy young male volunteers, 18-35 yr old, were selected for this study. Volunteers were excluded if they were obese (10%o or more above ideal weight) or if they had a family history of diabetes. Two intravenous insulin tolerance tests were performed on the majority of the subjects: a control test in which glucagon-free insulin was given alone and another test in which insulin was given while the patient was receiving either an alpha or a beta adrenergic blocking agent. Several subjects had three insulin tolerance tests, a control test and one with each of the adrenergic blocking agents, and some subjects received the adrenergic blocking agents without insulin. The series of tests on each subject was performed in random order and was completed within a 10 day period. With few exceptions, at least 1 day intervened between tests. A total of 52 studies was performed on these 21 individuals.
The subjects were instructed to abstain from smoking and to take nothing by mouth except water at 10 p.m. the night before the study. Each subject reported to the room used for clinical testing at 7 a.m. After the subject had been weighed, he was put to bed and a slow intravenous infusion of 0.85% NaCl was begun through a 20 gauge needle in an antecubital vein. The indwelling needle was used for withdrawal of blood samples as well as for injections of insulin and drugs. The needle was kept open by the saline infusion and no anticoagulants were given to the subject or were present in the sampling syringes. A sphygmomanometer was placed on the opposite arm to monitor blood pressure. Blood pressure and pulse rate were taken every 15 min throughout the experiment.
After a 30 min base line period, glucagon-free insulin (0.05 or 0.1 U/kg) was injected. With the exception of the first 15 min interval after insulin injection, blood samples were taken every 15 min during the control period and for 90 min after the insulin had been given. In the alpha adrenergic blockade experiments, phentolamine was infused at a rate of 0.5 mg/min by a Sage constant infusion pump beginning immediately before insulin administration and continuing throughout the remaining 90 min of the experiment. In the beta adrenergic blockade cxperiments, a "stat" dose of propranolol, 3 mg, was given intravenously and a constant infusion of propranolol at a rate of 0.08 mg/min was started immediately before insulin administration and was continued until the end of the experiment. Propranolol was not given to any subj ect with a resting pulse below 60 beats/min. On this basis, three subjects for whom propranolol experiments had been planned were rejected for that part of the study. In 11 studies (4 with alpha blockade and 7 with beta blockade) adrenergic blocking agents were given as described above, but without insulin. In four subjects, 500 mg of theophylline ethylenediamine was infused at a constant rate for 15 min at the end of the base line period. Blood samples were taken in all studies at the same intervals as in the experiments in which insulin was given.
Blood samples were collected in chilled heparinized tubes. Protein-free filtrates for blood glucose were made from 0.2 ml of blood immediately after the blood had been obtained. Blood glucose was determined by a glucose oxidase method (17) . Plasma free fatty acid (FFA) was measured by a modification of the Dole procedure on 1-ml aliquots of plasma (18) .
Plasma HGH was determined by a modification of the radioimmunoassay method of Schalch and Parker (19) utilizing 'I-labeled growth hormone and separating free from bound hormone by the double antibody technique.
Tracer and standards were prepared from highly puri- 
RESULTS
Alpha adre'nergic blockade during insulin hypoglycemia. The data shown in Fig. 1 demonstrate an inhibitory effect of alpha adrenergic blockade on plasma HGH concentrations during insulin hypoglycemia. Base line plasma HGH concentrations during the 30 min base line period were slightly higher in these and subsequent studies (3.1 + .2 m ug/ml) than those usually reported for overnight fasting male subjects (1). Our subjects were ambulatory before testing which may partially account for the higher plasma HGH concentrations. Glucagon-free insulin administration, 0.1 U/kg, resulted in peak plasma HGH concentrations at 45-75 min after injection. In the same subjects during a phentolamine infusion, 0. significantly greater (P < 0.02) in the experiments with insulin and propranolol than in those with insulin alone. Hypoglycemia and plasma FFA depression were more prolonged during beta adrenergic blockade (Fig. 6 ) and a possible role of these factors in the greater HGH response cannot be excluded. Summation of effects of adrenergic blockade on plasma HGH elevations and cardiovascular response to insulin hypoglycemia. Fig. 7 summarizes the effects of adrenergic receptor blockade on hypoglycemia-induced plasma HGH elevations. In The cardiovascular responses to insulin hypoglycemia during either alpha or beta adrenergic blockade are shown in Fig. 8 . The increase in pulse rate and pulse pressure during insulin hypoglycemia is accentuated by alpha receptor blockade with phentolamine and inhibited by beta receptor blockade with propranolol.
Alpha and beta adrenergic blockade in the absence of insulin hypoglycemia. Neither alpha adrenergic blockade (Fig. 9 ) nor beta adrenergic blockade (Fig. 10) 10). These results contrast with the pressive effect of propranolol on ( induced FFA elevations such as oc( "rebound" phase after insulin hypog 6). In the later case, propranolol FFA by blocking the lipolytic actioi mines. However, in the absence circulating catecholamines, phento have a greater suppressive effect or than propranolol through changes in tion (20) .
Effect of theophylline on plasma glucose, and plasma FFA. The( given by infusion (500 mg in 15 subjects to determine the influence of cyclic 3'5'-AMP phosphodiestera plasma HGH concentrations. No do on plasma HGH levels was observ increase in plasma FFA concen theophylline infusion (Fig. 11) . DISCUSSION The effect of catecholamines on gr secretion has been controversial (2, the present study, partial inhibition hormone response to hypoglycer adrenergic blockade with phentolam ?ophylline to indicate a stimulatory effect of catecholamines infusion on growth hormone secretion. In previous investigations showing no effect (6, 15) or even some inhibition (2, 16) of growth hormone concentrations in response to epinephrine, catecholamine-induced hyperglycemia may have suppressed growth hormone secretion. By utilizing endogenous catecholamines released as a result of hypoglycemia for the blocking experiments in this investigation, we avoided the possible masking effect of hyperglycemia on plasma HGH concentrations. The influence of catecholamines on growth hormone secretion might be exerted anywhere along the hypothalamic-hypophyseal axis and even perhaps at higher centers, but the hypothalamus seems the most likely site. Although the effect of hypoglycemia on growth hormone secretion may be only nia by alpha periments that the effect of hypoglycemia on ine would tend growth hormone secretion is entirely mediated by catecholamines since complete inhibition of HGH response could not be achieved with phentolamine. The growth hormone secretory mechanism is apparently sensitive to changes in blood glucose and not just to catecholamines released by hypoglycemia since elevations of blood glucose suppress HGH secretion (1) . Catecholamines may merely modify the stimulatory effect of hypoglycemia on HGH release. Investigations by Sutin have shown an effect of insulin hypoglycemia on the evoked electrical potential recorded from a probe in the ventromedial nucleus of the hypothalamus after stimulation of the amygdala and septal nuclei (25) . These changes in electrical potential from the ventromedial nucleus could be reproduced by injection of norepinephrine into the nucleus (26) . Norepinephrine modified the amplitude of electrical response in the ventromedial nucleus to stimuli from other nuclei but did not initiate a response.
The stimulatory effect of catecholamines on growth hormone secretion has important implications as practically all of the recognized stimuli for growth hormone secretion, with the exception of amino acid infusion and estrogens, invoke a catecholamine response. Even small decreases in blood glucose (less than 10 mg/100 ml) which have been reported to elevate plasma HGH are accompanied by increased urinary catecholamines (6) . In addition, the sympathetic tone in the hypothalamus may be important in the secretory regulation of other pituitary hormones. Hypothalamic catecholamine-depleting agents such as reserpine have been shown to influence gonadotropin secretion (27) as well as to inhibit the growth hormone response to hypoglycemia (28) . Vasopressin secretion also is probably modified by adrenergic tone in the hypothalamus (29) .
The present study characterized the growth hormone response to catecholamines in terms of alpha and beta adrenergic receptors. During insulin hypoglycemia the inhibitory effect of alpha blockade on growth hormone secretion was pronounced while the stimulatory effect of beta blockade was less impressive and was associated with more prolonged hypoglycemia and lower plasma FFA concentrations. More prolonged hypoglycemia probably was not responsible for the enhanced HGH response during beta blockade as studies in monkeys during insulin hypoglycemia have shown that growth hormone hypersecretion occurs while blood glucose concentrations are falling but return to normal even though plasma glucose concentrations remain depressed (30) . Limited data on the effect of plasma FFA on growth hormone levels are available. Schalch and Kipnis were unable to demonstrate an effect of plasma FFA elevations on plasma HGH concentrations in three subjects given a fat meal followed by heparin (31) . However, preliminary data from Dr. K. Shizume in Tokyo (personal communication) have suggested that elevations of plasma growth hormone concentrations by nicotinic acid may be related to the fall in plasma FFA. Data by Abramson, Arky, and Woeber, which showed a modest increase in hypoglycemia-induced plasma HGH elevations during beta adrenergic blockade, support our findings (32) .
The present studies demonstrate a definite stimulatory effect of alpha adrenergic receptors and a possible inhibitory effect of beta adrenergic receptors on growth hormone secretion. This pattern is the opposite of the adrenergic control mechanism for insulin secretion where it has been shown that alpha receptors inhibit (33) and beta receptors stimulate (34) insulin release. Since the predominant effect of catecholamines on hormonal regulation appear to be through alpha receptors, another remarkable homeostatic mechanism to maintain the constancy of the internal milieu is observed. During hypoglycemia, catecholamines inhibit insulin secretion and assist in promoting a rise in plasma HGH which antagonizes the action of insulin and also increases plasma FFA which may be used for energy requirements.
The lack of effect of adrenergic blockade or theophylline, an inhibitor of cyclic 3'5'-AMP phosphodiesterase activity, on plasma HGH concentrations in the absence of hypoglycemia probably negates a significant role of the adrenergic nervous system in control of resting plasma HGH levels.
